Home › Premarket Biotech Digest: Breast Cancer Therapies, Anavex's Milestone, Praluent EU Approval
 

Keywords :   


Premarket Biotech Digest: Breast Cancer Therapies, Anavex's Milestone, Praluent EU Approval

2015-09-29 16:11:27| Biotech - Topix.net

Targeted therapies in breast cancer are the latest developments in this area of therapeutics. Although these therapies sometimes cause serious side effects, for example, damage to heart muscles in some HER2 inhibitors, they offer a non-surgical option for treating breast cancer.

Tags: approval cancer breast digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 4
29.06Tropical Storm Beryl Wind Speed Probabilities Number 4
29.06Tropical Storm Beryl Public Advisory Number 4
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Forecast Advisory Number 4
29.06Tropical Storm Beryl Public Advisory Number 3A
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
More »